Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants

Vaccine

Volumn 17, Issue 7-8, 1999, Pages 887-892

  Gonzalo, Rosa M ^a   Rodríguez, Dolores ^a   García Sastre, Adolfo ^b   Rodríguez, Juan Ramón ^a   Palese, Peter ^b   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CD8+ T cells; HIV 1 env; Influenza and vaccinia virus recombinants

Indexed keywords

GAMMA INTERFERON; RIBONUCLEOPROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS RECOMBINANT;

AMINO ACID SEQUENCE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; GENE PRODUCTS, ENV; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA VACCINES; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; VACCINES, COMBINED; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0344096503     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00274-6     Document Type: Article

References (32)

1. Earl P.L., Moss B., Morrison P., Wehrly K., Nishio J., Chesebro B. T-lymphocytes priming and protection against Friend leukemia by vaccinia-retrovirus Env gene recombinants. Science. 234:1986;728-730.
2. McMichael A.J., Walker B.D. Cytotoxic T lymphocyte epitopes: implications for HIV vaccines. AIDS. 8:(1):1994;S155-S173.
3. Walker B.D., Plata F. Cytotoxic T lymphocytes against HIV. AIDS. 4:1990;177-184.
4. + lymphocyte can control HIV infection in vitro by supressing virus replication. Science. 234:1986;1563-1566.
5. Engelhard V.H. Structure of peptides associated with class I and class II MHC molecules. Annual Review of Immunology. 12:1994;181-207.
6. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., Farthing C., Ho D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. Journal of Virology. 68:1994;4650-4655.
7. Carmichel A., Jim X., Sissons P., Borysewicz L. Quantitative analysis of the human immunodeficiency virus type I (HIV-1)-specific cytotoxic T lymphocyte (CTL) response to HIV-1 and Epstein-Barr virus in late disease. Journal of Experimental Medicine. 177:1993;249-256.
8. Klein M.R., Van Baalen C.A., Holwerda A.M., Kerkhof Garde S.R., Bende R.J., Keet I.P.M., Eeftinck-Schattenkerk J.K., Osterhaus A.D., Schuitemaker H., Miedema F. Kinetics of gag specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term symtomatics. Journal of Experimental Medicine. 181:1995;1365-1372.
9. Cao Y., Qin L., Zhang L., Safrit J., Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type I infection. New England Journal of Medicine. 322:1995;201-208.
10. Rinaldo C., Huang X.L., Fan Z., Ding M., Beltz L., Logar A., Panicali D., Mazzara G., Liebmann J., Cottrill M., Gupta D. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocytes activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. Journal of Virology. 69:1995;5838-5842.
11. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety. Proceedings of the National Academy of Sciences USA. 93:1996;11341-11348.
12. + T-cell-mediated protective immunity against malaria. Proceedings of the National Academy of Sciences USA. 90:1993;5214-5218.
13. Walker M.C., Fast P.E. Clinical trials of candidate AIDS vaccines. AIDS. 8:(1):1994;S213.
14. Graham B.S., Wright P.F. Candidate AIDS vaccines. New England Journal of Medicine. 33:1995;1331-1339.
15. Girard M., Meignier B., Barre-Sinoussi F., Kieny M.P., Matthews T., Muchmore E., Nara P.L., Wei Q., Rimsky L., Weinhold K., Fultz P. Vaccinia-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type I. Journal of Virology. 69:1995;6239-6248.
16. Berman P.W., Murthy K.K., Wrin T., Vennari J.C., Cobb E.K., Eastman D.J., Champe M., Nakamura G.R., Davison D., Powell M.F., Bussiere J., Francis D.P., Matthews T., Gregory T.J., Obijeski J.F. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type I. Journal of Infectious Diseases. 173:1996;52-59.
17. Rushe J.R., Jahaverian K., McDanal C., Petro J., Lynn D.L., Grimalia R., Langlois A., Gallo R.C., Arthur L.O., Fischinger P.J., Bolognesi D.P., Putney S.D., Mathews T.J. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-aminoacid sequence of viral envelope gp120. Proceedings of the National Academy of Sciences USA. 85:1988;3192-3202.
18. Jahaverian K., Langlois A.J., McDanal C., Ross K.L., Eckler L.I., Cindy L., Jellis L., Profy A.T., Rusche J.R., Bolognesi D.P., Putney S.D., Mathews T.J. Principal neutralizing domain of the human immunodeficiency virus type I envelope protein. Proceedings of the National Academy of Sciences USA. 86:1989;6768-6772.
19. Putney S., Javaherian K., Profy A., Emini E., Langlois A., Ross K. et al. Human retroviruses. New York: Liss, 1990. p. 323-335.
20. Takahashi H, Cohen J, Hosmalin A, Cease K.B, Houghten R, Cornette J.L, DeLisi C, Moss B, An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted immune cytotoxic T lymphocytes. Proceedings of the National Academy of Sciences USA 1988;:3105-3109.
21. Lesarte J.J., Sarobe P., Gullón A., Prieto J., Borrás-Cuesta F. Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. Cellular Immunology. 141:1992;211-218.
22. Takahashi H., Nakagawa Y., Pendleton C., Hougten R., Yokomuro K., Germaine R.N., Berzofsky J.A. Induction of broadly cross-reactive T cells recognizing and HIV-1 envelope determinant. Science. 255:1992;333-336.
23. Takahashi H., Germaine R.N., Moss B., Berzofsky J.A. An immunodominant class-I-restricted cytotoxic T lymphocytes determinant on human immunodeficiency virus type I induces CD4 class II-restricted help for itself. Journal of Experimental Medicine. 171:1990;571-576.
24. Li S., Polonis V., Isobe H., Zaghouani H., Guinea R., Moran T., Bona C., Palese P. Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. Journal of Virology. 67:1993;6659-6666.
25. Enami M., Palese P. High-efficiency formation of influenza virus transfectants. Journal of Virology. 65:1991;2711-2713.
26. Rodríguez D., Rodríguez J.R., Rodríguez J.F., Trauber D., Esteban M. Highly attenuated vaccinia virus for the generation of safe recombinant viruses. Proceedings of the National Academy of Sciences USA. 86:1989;1287-1291.
27. + T cells using an ELISPOT assay. Journal of Immunological Methods. 181:1994;45-54.
28. + T cell responses induced by recombinant influenza and vaccinia viruses. Cellular Immunology. 173:1996;96-107.
29. Matsushita S., Robert-Guroff M., Rusche J., Koito A., Hattori T., Javanesian K., Takatsuki K., Putney S. Characterization of a Human Immunodeficiency Virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. Journal of Virology. 62:1988;2107-2114.
30. Karron R.A., Steinhoff M.C., Subbarao E.K., Wilson M.H., Macleod K., Clements M.L., Fries L.H., Murphy B.R. Safety and immunogenicity of a cold-adapted influenza A (HIN1) reassortant virus vaccine administered to infants less than six months of age. Pediatric Infectious Diseases Journal. 14:1995;10-16.
31. Paez E., Dallo S., Esteban M. Generation of a dominant 8mDa deletion at the left terminus of vaccinia virus DNA. Proceedings of the National Academy of Sciences USA. 82:1985;3365-3369.
32. Carroll M.W., Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in nonhuman mammalian cell line. Virology. 238:1997;198-211.